Financial Performance - The company's operating revenue for Q3 2023 was CNY 473,838,338.51, representing a slight increase of 0.51% compared to the same period last year, but a significant decline of 26.64% year-to-date [25]. - The net profit attributable to shareholders for Q3 2023 was CNY 146,146,851.85, an increase of 16.64% year-on-year, but a decrease of 51.50% year-to-date [25]. - The gross profit margin for the period was 80.66%, down 2.62 percentage points year-on-year due to changes in sales structure and rising production costs [22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 141,207,493.39, up 17.26% year-on-year [25]. - The company reported a total cash inflow from operating activities of ¥1.88 billion, while cash outflow was ¥1.30 billion, resulting in a net cash flow of ¥590 million [46]. - Net profit for the current period is ¥420,436,301.43, a decline of approximately 51.6% compared to ¥869,103,293.45 in the previous period [70]. - The total comprehensive income for the current period is ¥420,436,301.43, down from ¥870,912,578.70 in the previous period, a decrease of approximately 51.7% [71]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,496,117,069.50, reflecting a 1.53% increase from the end of the previous year [25]. - Total liabilities rose by 30.20% to ¥2,373,461,054.62, mainly from increased bank loans and funds from the employee stock ownership plan [28]. - The total assets amount to ¥5,496,117,069.50, compared to ¥5,413,415,651.96 in the previous period, showing a slight increase of about 1.5% [59]. - The total equity attributable to shareholders of the parent company decreased to ¥3,109,706,337.72 from ¥3,574,282,437.69, a decline of about 13.0% [59]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was CNY 590,042,426.16, showing a 12.37% increase [25]. - Cash received from operating activities increased by 52.88% to ¥111,126,926.30, attributed to higher bank deposit interest received [29]. - The net cash flow from operating activities was approximately ¥590 million, an increase of 12.4% from ¥525 million in the same period last year [47]. - The net cash flow from financing activities was negative at -¥338,981,095.59, an improvement of 37.87% compared to the previous year [30]. - Net cash flow from financing activities was -$338.98 million, compared to -$545.64 million in the previous period [74]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,372 [50]. - The largest shareholder, Dong Fan, holds 43.98% of shares, totaling 355,131,867 shares [50]. - The company has repurchased a total of 5,958,154 shares, accounting for 0.74% of the total share capital, with a total transaction amount of 132.54 million RMB [54]. Research and Development - The company plans to continue increasing R&D investment and market promotion to address operational challenges and future growth [22]. - Research and development expenses for the current period are ¥176,357,010.23, an increase from ¥162,284,135.93 in the previous period, indicating a growth of approximately 8.6% [69]. Other Financial Metrics - The company’s weighted average return on net assets decreased by 13.93% to 11.17% year-to-date [25]. - The company’s financial expenses increased by 57.89% to CNY -26,845,539.47, primarily due to higher interest income compared to the same period last year [20]. - The company reported a financial expense of -¥26,845,539.47, compared to -¥17,002,865.25 in the previous period, reflecting an increase in financial costs [70]. - Earnings per share (EPS) for the current period is ¥0.53, down from ¥1.10 in the previous period [71].
健帆生物(300529) - 2023 Q3 - 季度财报